Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer.
from Medindia Health News http://bit.ly/2IaS9Mj
No comments:
Post a Comment